1 to 6 of 6 literature results

• PhRMA Survey on the Conduct of First-in-Human Clinical Trials Under Exploratory Investigational New Drug Applications.

  The FDA guidance on exploratory IND studies is intended to enable sponsors to move ahead more efficiently with the development of promising candidates…

  Authors: Adel H Karara, Timi Edeki, James McLeod, Alfred P Tonelli, John A Wagner

  Source: Journal of clinical pharmacology. 2010 Apr

  View Full Text

• Systemic availability of the active metabolite hydroxy-fasudil after administration of fasudil to different sites of the human gastrointestinal tract.

  This study evaluated the gastrointestinal absorption of fasudil, a novel Rho kinase inhibitor for the treatment of stable angina, at different sites u…

  Authors: Peter H Hinderling, Adel H Karara, Ben Tao, Maria Pawula, Ian Wilding, Ming Lu

  Source: Journal of clinical pharmacology. 2007 Jan

  View Full Text

• Pharmacokinetics and pharmacodynamics of drospirenone-estradiol combination hormone therapy product coadministered with hydrochlorothiazide in hypertensive postmenopausal women.

  The effects of combination hormone therapy of drospirenone (DRSP), a novel progestin with antialdosterone properties, and 17beta-estradiol (E2) on hyd…

  Authors: Adel H Karara, Vladimir Hanes, Alberto Alonso, Pingping Ni, Nagaraju Poola, Rose Silang, Hartmut Blode, Richard A Preston

  Source: Journal of clinical pharmacology. 2007 Oct

  View Full Text

• Simultaneous estradiol and levonorgestrel transdermal delivery from a 7-day patch: in vitro and in vivo drug deliveries of three formulations.

  A new drug-in-adhesive transdermal patch was developed to deliver both estradiol and levonorgestrel through the skin over a 7-day period, but at diffe…

  Authors: Lester I Harrison, Christian Zurth, Clemens Gunther, Adel H Karara, Armen Melikian, Ralph Lipp

  Source: Drug development and industrial pharmacy. 2007 Apr

  View Full Text

• Additive effect of drospirenone/17-beta-estradiol in hypertensive postmenopausal women receiving enalapril.

  BACKGROUND: Aldosterone has been implicated in the pathogenesis of progressive cardiovascular disease. Drospirenone (DRSP) is a novel progestin with a…

  Authors: Richard A Preston, Alberto Alonso, Darlene Panzitta, Paul Zhang, Adel H Karara

  Source: American journal of hypertension. 2002 Sep

  View Full Text

• Randomized, placebo-controlled trial of the effects of drospirenone-estradiol on blood pressure and potassium balance in hypertensive postmenopausal women receiving hydrochlorothiazide.

  OBJECTIVE: Drospirenone (DRSP), a spironolactone analog with aldosterone antagonist activity, is a novel progestogen developed for use as hormone ther…

  Authors: Richard A Preston, Paul M Norris, Alberto B Alonso, Pingping Ni, Vladimir Hanes, Adel H Karara

  Source: Menopause (New York, N.Y.). 2007 May-Jun

  View Full Text